GRI Bio, Inc. (GRI)
1.93
+0.09
(+4.89%)
USD |
NASDAQ |
Sep 18, 16:00
1.90
-0.03
(-1.55%)
After-Hours: 20:00
GRI Bio Debt to Equity Ratio : 0.0043 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0043 |
| March 31, 2026 | 0.0055 |
| December 31, 2025 | 0.0118 |
| September 30, 2025 | 0.0421 |
| June 30, 2025 | 0.0289 |
| March 31, 2025 | 0.0896 |
| December 31, 2024 | 0.0295 |
| September 30, 2024 | 0.0358 |
| June 30, 2024 | 0.0299 |
| March 31, 2024 | 0.0543 |
| December 31, 2023 | 0.0541 |
| September 30, 2023 | 0.0126 |
| June 30, 2023 | 0.0102 |
| March 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2022 | -0.4142 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.029 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.02 |
| December 31, 2020 | -0.2311 |
| September 30, 2020 | -14.29 |
| June 30, 2020 | 0.3653 |
| March 31, 2020 | |
| December 31, 2019 | 0.1058 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 11.38M |
| Total Liabilities (Quarterly) | 1.10M |
| Shareholders Equity (Quarterly) | 10.28M |
| Current Ratio | 10.30 |
| Net Debt Paydown Yield | 0.33% |